These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32755653)

  • 1. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
    Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.
    Catteau L; Dauby N; Montourcy M; Bottieau E; Hautekiet J; Goetghebeur E; van Ierssel S; Duysburgh E; Van Oyen H; Wyndham-Thomas C; Van Beckhoven D;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106144. PubMed ID: 32853673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
    Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
    JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
    Lagier JC; Million M; Gautret P; Colson P; Cortaredona S; Giraud-Gatineau A; Honoré S; Gaubert JY; Fournier PE; Tissot-Dupont H; Chabrière E; Stein A; Deharo JC; Fenollar F; Rolain JM; Obadia Y; Jacquier A; La Scola B; Brouqui P; Drancourt M; Parola P; Raoult D;
    Travel Med Infect Dis; 2020; 36():101791. PubMed ID: 32593867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
    Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ;
    Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
    Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
    PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
    [No Abstract]   [Full Text] [Related]  

  • 14. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
    Arshad S; Kilgore P; Chaudhry ZS; Jacobsen G; Wang DD; Huitsing K; Brar I; Alangaden GJ; Ramesh MS; McKinnon JE; O'Neill W; Zervos M;
    Int J Infect Dis; 2020 Aug; 97():396-403. PubMed ID: 32623082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
    Giaime P; Guenoun M; Pedinielli N; Narbonne H; Bergounioux JP; Solas C; Guilhaumou R; Sampol J; Ollier J; Sichez H; Serveaux M; Brunner F; Bataille S
    Nephrol Dial Transplant; 2020 Aug; 35(8):1346-1353. PubMed ID: 32844224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality.
    Rivera-Izquierdo M; Valero-Ubierna MDC; R-delAmo JL; Fernández-García MÁ; Martínez-Diz S; Tahery-Mahmoud A; Rodríguez-Camacho M; Gámiz-Molina AB; Barba-Gyengo N; Gámez-Baeza P; Cabrero-Rodríguez C; Guirado-Ruiz PA; Martín-Romero DT; Láinez-Ramos-Bossini AJ; Sánchez-Pérez MR; Mancera-Romero J; García-Martín M; Martín-delosReyes LM; Martínez-Ruiz V; Jiménez-Mejías E
    Med Clin (Barc); 2020 Nov; 155(9):375-381. PubMed ID: 32773165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
    Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
    Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain.
    Goicoechea M; Sánchez Cámara LA; Macías N; Muñoz de Morales A; Rojas ÁG; Bascuñana A; Arroyo D; Vega A; Abad S; Verde E; García Prieto AM; Verdalles Ú; Barbieri D; Delgado AF; Carbayo J; Mijaylova A; Acosta A; Melero R; Tejedor A; Benitez PR; Pérez de José A; Rodriguez Ferrero ML; Anaya F; Rengel M; Barraca D; Luño J; Aragoncillo I
    Kidney Int; 2020 Jul; 98(1):27-34. PubMed ID: 32437770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.